Early treatment with anti-VLA-4 mAb can prevent the infiltration and/or development of pathogenic CD11b+CD4+ T cells in the CNS during progressive EAE.
about
Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosisAntibody blockade of CLEC12A delays EAE onset and attenuates disease severity by impairing myeloid cell CNS infiltration and restoring positive immunity.Multiple functional therapeutic effects of TnP: A small stable synthetic peptide derived from fish venom in a mouse model of multiple sclerosis.Further understanding of the immunopathology of multiple sclerosis: impact on future treatments.Sex Bias in Pathogenesis of Autoimmune Neuroinflammation: Relevance for Dimethyl Fumarate Immunomodulatory/Anti-oxidant Action.Prophylactic Effect of BIO-1211 Small-Molecule Antagonist of VLA-4 in the EAE Mouse Model of Multiple Sclerosis.
P2860
Early treatment with anti-VLA-4 mAb can prevent the infiltration and/or development of pathogenic CD11b+CD4+ T cells in the CNS during progressive EAE.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Early treatment with anti-VLA- ...... he CNS during progressive EAE.
@ast
Early treatment with anti-VLA- ...... he CNS during progressive EAE.
@en
type
label
Early treatment with anti-VLA- ...... he CNS during progressive EAE.
@ast
Early treatment with anti-VLA- ...... he CNS during progressive EAE.
@en
prefLabel
Early treatment with anti-VLA- ...... he CNS during progressive EAE.
@ast
Early treatment with anti-VLA- ...... he CNS during progressive EAE.
@en
P2093
P2860
P1433
P1476
Early treatment with anti-VLA- ...... the CNS during progressive EAE
@en
P2093
Kouichi Ito
Suhayl Dhib-Jalbut
P2860
P304
P356
10.1371/JOURNAL.PONE.0099068
P407
P577
2014-06-04T00:00:00Z